Drug intelligence / Profile preview

RT004

Development stage: Preclinical
Lead developer: Revio Therapeutics
Modality: Small Molecules
Administration: Rectal, Topical

Overview

RT004 is a preclinical-stage repurposed drug candidate being developed by Revio Therapeutics for the treatment of mucosal conditions. The drug is delivered via a specialized rectal or topical mucoadhesive gel formulation designed to optimize delivery to mucosal tissues. As part of Revio's repurposing pipeline, RT004 utilizes an existing approved active pharmaceutical ingredient pivoted toward a new therapeutic indication. While the specific molecular target and active ingredient have not been publicly disclosed, the program is currently in the prototype proof-of-concept stage of preclinical development.

Beyond the preview

Go deeper on RT004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT004.

Explore the full profile